Results 101 to 110 of about 13,979 (215)

Genetic Ablation and Multi‐Omics Profiling Reveal CEP55 as a Key Driver of Tumorigenesis in Diverse Cancer Models

Advanced Science, Volume 13, Issue 58, 19 October 2026.
Genetic ablation of Cep55 in Pten‐deficient mouse models delays tumorigenesis. Integrated multi‐omics analyses (proteomics, phosphoproteomics, and spatial transcriptomics) reveal that CEP55 regulates oncogenic signaling (RAS/ERK, PI3K/AKT), integrin/FAK‐mediated adhesion, extracellular matrix (ECM) remodeling, and endocytosis.
Behnam Rashidieh, Yuanhao Yang, Amanda Louise Bain, Phillip Theron, Catharina Vosloo, Sahar Keshvari, Parinaz Ahangar, Brydie Bowden, Simon M. Tria, Ben B. Wang, Sandra Isenmann, Nicholas J. Westra van Holthe, Zherui Xiong, Hani Vu, Sowmya Sharma, Asmerom Sengal, J. Alejandro Lopez, John Finnie, Antonella Papa, Pascal H.G. Duijf, Quan Nguyen, Pirjo M. Apaja, Kum Kum Khanna   +22 more
wiley   +1 more source

circPVT1 Inhibits the Proliferation and Aids in Prediction of the Prognosis of Bladder Cancer

Pharmacogenomics and Personalized Medicine
Hongyi Zhou,1,* Xueping Cui,2,* Leilei Zhu,1 Zhuoqun Xu,1 Zhuo Wang,3 Jianfeng Shao4 1Department of Urology, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi, Jiangsu Province, 214023, People’s Republic of China ...
Zhou H, Cui X, Zhu L, Xu Z, Wang Z, Shao J   +5 more
doaj  

Pan‐Cancer Analysis of the Immunomodulatory Roles and Prognostic Value of PDXP and Experimental Verification in SKCM

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Multiple public databases, including TCGA, GEO, and TARGET, were utilized to comprehensively analyze pyridoxal phosphatase (PDXP) expression profiles across 34 cancer types. We further explored the associations of PDXP expression with clinicopathological features, tumor immune microenvironment, genomic heterogeneity, functional signaling ...
Yingjian Hu, Xinzhu Zeng, Wei Cao, Jianhao Jiao, Yuan Zhao, Jun Wang   +5 more
wiley   +1 more source

Mesothelin as Biomarker and Therapeutic Target for Immunotherapy in Cancer

MedComm, Volume 7, Issue 10, October 2026.
Mesothelin overexpression activate important pathways like nuclear factor k‐light‐chain‐enhancer of activated B cells (NF‐κB) and interleukin‐6 (IL‐6). This in turn causes numerous cancers, such as pancreatic and ovarian cancers. MSLN‐targeting immunotherapies, like monoclonal antibodies, have shown efficacy.
Manoj Kumar Gupta, Ramakrishna Vadde, Ganji Purnachandra Nagaraju   +2 more
wiley   +1 more source

NTAQ1 Promotes Hepatocellular Carcinoma Growth by Facilitating the Protein Degradation of the Tumor Suppressor PRDM2

Cancer Science, Volume 117, Issue 10, Page 2803-2818, October 2026.
Copy number variation analysis in The Cancer Genome Atlas identified NTAQ1 as a potential driver of HCC progression. NTAQ1 accelerates tumor growth by promoting the degradation of the tumor suppressor protein PRDM2, thereby impairing DNA repair and suppressing apoptosis. These findings indicate that NTAQ1 could be a valuable target for the treatment of
Tomohiko Ikehara, Hajime Otsu, Taro Tobo, Kiyotaka Hosoda, Tadashi Abe, Masahiro Hashimoto, Yusuke Nakano, Katsushi Dairaku, Yuya Ono, Yuki Miyata, Chihiro Matsumoto, Takanari Tatsumi, Satoshi Higuchi, Takashi Ofuchi, Akinori Tsujimoto, Yuki Ando, Qingjiang Hu, Yusuke Yonemura, Akira Shimizu, Takaaki Masuda, Yuji Soejima, Koshi Mimori   +21 more
wiley   +1 more source

Image_12_Four types of adenine-related RNA modification writers -mediated molecular subtypes contribute to predicting clinical outcomes and treatment options in bladder cancer.jpeg

, 2023
RationaleRNA modifications, containing m6A, m1A, alternative polyadenylation and adenosine-to-inosine RNA editing, involve in critical cancerous immunity and cancerous processes. However, the functional roles of RNA modification writers in bladder cancer
Wen Wen (596162), Ying Chen (9697), Yao Zhang (134381)   +2 more
core   +1 more source

CDCA3-MYC positive feedback loop promotes bladder cancer progression via ENO1-mediated glycolysis

Journal of Experimental & Clinical Cancer Research
Background Bladder cancer (BLCA) ranks among the most prevalent malignancies of the urinary system, with its clinical diagnosis predominantly reliant on invasive procedures.
Dexin Shen, Xiang Yu, Xuefeng Fan, Yu Liang, Dongmei Lu, Zongpan Ke, Lei Wang, Ping Xiang, Jun Xiao   +8 more
doaj   +1 more source

The Cancer Genome Atlas Urothelial Bladder Carcinoma Collection (TCGA-BLCA)

, 2016
D., M., ., . ., ., ., . (2016): The Cancer Genome Atlas Urothelial Bladder Carcinoma Collection (TCGA-BLCA). Ecologica Montenegrina 6: 34-36, DOI: 10.7937/k9/tcia.2016.8lng8xdr, URL: http://dx.doi.org/10.7937/k9/tcia.2016 ...
D., M.
openaire   +1 more source

The correlation between SCD expression and immune cells infiltration levels in BLCA、CESC、KICH and LGG.

(A) The expression level of SCD was significantly correlated with infiltrating levels of different immune cells in BLCA、CESC and LGG. (TIF)
Jiang Jiang (1513975), Yi Wang (32470), Shu Wang (180520), Yun Li (692280), Rongfeng Liao (3914516)   +4 more
core   +1 more source

Image_1_Four types of adenine-related RNA modification writers -mediated molecular subtypes contribute to predicting clinical outcomes and treatment options in bladder cancer.jpeg

, 2023
RationaleRNA modifications, containing m6A, m1A, alternative polyadenylation and adenosine-to-inosine RNA editing, involve in critical cancerous immunity and cancerous processes. However, the functional roles of RNA modification writers in bladder cancer
Wen Wen (596162), Ying Chen (9697), Yao Zhang (134381)   +2 more
core   +1 more source